What guidance did The Joint's management provide for the next earnings period?

What does The Joint do and what are its main business segments?

Did The Joint beat or miss consensus estimates last quarter?

What factors drove the changes in The Joint's revenue and profit?

What is The Joint's gross profit margin?

What is The Joint's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for The Joint year over year?

What were the key takeaways from The Joint’s earnings call?

- **Revenue Recovery**: Continuing ops revenue +6%, EBITDA up 36% to $3.3M, driven by refranchising and cost cuts.
- **Tech Adoption**: Mobile app downloaded 178k times, 18% new patient engagement with gamified wellness tracking.
- **Pricing Strategy**: Testing 3 price tiers across 200 clinics to balance affordability with margin optimization.
- **Refranchising Momentum**: 40 corporate clinics sold, 33 in final negotiation stages, targeting 100% franchise model by 2026.
- **Financial Strength**: $29.7M cash, $12M buyback plan, and 2026 guidance for positive comps and EBITDA growth.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 revenue from continuing operations increased 6%, driven by refranchising efforts and cost reductions. Adjusted EBITDA rose 36% to $3.3 million. 
- **AI & Technology**: Launched a patient-facing mobile app with 178,000 downloads, achieving 18% adoption among new patients. Testing gamification features like badges for engagement.
- **Refranchising Progress**: Sold 8 franchise licenses (vs. 7 last year), with 149 in development. Closed 3 corporate clinics and refranchised 40 so far.
- **Pricing Strategy**: Testing 3 price increase tiers across 200 clinics to balance affordability with margin optimization.
- **Marketing Shift**: Shifted $500/month per clinic from local to national campaigns, leveraging AI-driven search optimization.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $855k (vs. -$3.2M last year). Adjusted EBITDA from continuing ops up 36% to $1.4M. Unrestricted cash $29.7M.
- **Cost Efficiency**: Reduced G&A expenses 1%, cost of revenues down 6% via refranchising. Extended $12M stock buyback plan.
- **Guidance Update**: 2025 system-wide sales $530-534M, comp sales -1% to flat. 2026 target: 100% franchised model with improved margins.

**【Q&A Key Highlights】**
- **Refranchising Timeline**: 45 Southern California clinics in final negotiation stages. 33 remaining clinics under asset purchase agreements.
- **Pricing Pilot Results**: Testing 3 tiers of price increases across diverse geographies to gauge patient sensitivity.
- **App Engagement**: Early metrics show high patient experience scores, with features like credit card updates and treatment plan tracking.
- **Breakeven Improvement**: New clinics now reach breakeven in <1 year (vs. 2+ years prior), using preopening lead generation protocols.
- **Liquidity Management**: Extended $20M credit line maturity to 2027. Q3 share buybacks $2.3M, with $2.7M additional purchases post-quarter end.

The Joint Corp. (JYNT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

JYNT

JYNT fundamentals

You can ask Aime